Read by QxMD icon Read

Tarc lymphoma

Wouter J Plattel, Zainab N D Alsada, Gustaaf W van Imhoff, Arjan Diepstra, Anke van den Berg, Lydia Visser
Soluble Galectin-1 (sGal-1, also termed LGALS1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine (TARC, also termed CCL17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and clinical treatment response...
September 9, 2016: British Journal of Haematology
(no author information available yet)
No abstract text is available yet for this article.
February 2016: Clinical Advances in Hematology & Oncology: H&O
Annarosa Cuccaro, Salvatore Annunziata, Elisa Cupelli, Maurizio Martini, Maria L Calcagni, Vittoria Rufini, Manuela Giachelia, Francesca Bartolomei, Eugenio Galli, Francesco D'Alò, Maria T Voso, Giuseppe Leone, Alessandro Giordano, Luigi M Larocca, Stefan Hohaus
Early response evaluation with [(18) F]fluordeoxyglucose (FDG) positron emission tomography after 2 cycles of chemotherapy (interim PET) has been indicated as the strongest predictor for outcome in classical Hodgkin lymphoma (HL). We studied the prognostic role of the number of tumor-infiltrating CD68+ cells and of the plasma levels of TARC (thymus and activation-regulated chemokine) in the context of interim PET in 102 patients with classical HL treated with Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD)...
March 2016: Cancer Medicine
Lucia Farina, Francesca Rezzonico, Francesco Spina, Anna Dodero, Arabella Mazzocchi, Flavio Crippa, Alessandra Alessi, Serena Dalto, Simonetta Viviani, Paolo Corradini
Patients with relapsed and refractory Hodgkin lymphoma (HL) may experience long-term survival after allogeneic stem cell transplantation (alloSCT), but disease recurrence represents the main cause of treatment failure. Positron-emission tomography (PET)-positive patients after alloSCT have a dismal outcome. Serum thymus and activation-regulated chemokine (TARC) is produced by Reed-Sternberg cells and may be a marker of disease. Our study aimed at assessing whether TARC levels after alloSCT correlated with disease status and whether TARC monitoring could increase the ability to predict relapse...
December 2014: Biology of Blood and Marrow Transplantation
Osamu Yoshie, Kouji Matsushima
Chemokines and chemokine receptors orchestrate cell migration and homing in the body. Humans have at least 44 chemokines that are further classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C and CX3C. All the known chemokine receptors are seven transmembrane-type receptors. Humans have 18 chemotactic and 5 atypical non-chemotactic (recycling or scavenging) receptors. CC chemokine receptor 4 (CCR4) is the receptor for two CC chemokine ligands (CCLs)-CCL17 (also called thymus- and activation-regulated chemokine) and CCL22 (macrophage-derived chemokine)...
January 2015: International Immunology
Preethi Reddy Marri, Lucy S Hodge, Matthew J Maurer, Steven C Ziesmer, Susan L Slager, Thomas M Habermann, Brian K Link, James R Cerhan, Anne J Novak, Stephen M Ansell
PURPOSE: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. EXPERIMENTAL DESIGN: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls...
December 15, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Simon J Harrison, Andy K Hsu, Paul Neeson, Anas Younes, Anna Sureda, Andreas Engert, H Miles Prince, Martha Li, Paula Savage, Roberto Bugarini, Denise Williams, Margaret Squier, David S Ritchie
Abstract In a phase 2 trial of panobinostat in 129 patients with relapsed or refractory Hodgkin lymphoma, exploratory analyses of chemokines and cytokines were prospectively performed in 109 patients to determine their association with clinical outcomes. Patients were categorized into two groups (reductions > median and reductions ≤ median) based on percentage change from baseline of log10 transformed measurements. Thymus and activation-regulated chemokine (TARC) was most strongly associated with clinical outcome...
May 2014: Leukemia & Lymphoma
Hiroshi Kato, Chiyo Saito, Erika Ito, Takuya Furuhashi, Emi Nishida, Takashi Ishida, Ryuzo Ueda, Hiroshi Inagaki, Akimichi Morita
BACKGROUND: Mycosis fungoides (MF) is a malignant lymphoma characterized by expansion of CD4(+) memory T-cell clones. Infiltrating cells express CCR4, which is attracted to CC chemokine ligands 17 and 22 (thymus and activation-regulated chemokine [TARC]/CCL17 and TARC/CCL22). Bath-psoralen plus ultraviolet A (PUVA) is effective against MF. In patients with psoriasis, bath-PUVA induces circulating regulatory T cells (Tregs), which suppress effector T cells. To understand the mechanisms in MF, we analyzed lesion-infiltrating cells before and after bath-PUVA therapy...
June 2013: Clinical Lymphoma, Myeloma & Leukemia
Maike Sauer, Annette Plütschow, Ron D Jachimowicz, Dominik Kleefisch, Katrin S Reiners, Sabine Ponader, Andreas Engert, Elke Pogge von Strandmann
Hodgkin lymphoma (HL) has become one of the best curable cancers. However, better biomarkers are needed for outcome prediction that would allow protecting patients from over- or under-dosing of treatment. Thymus and activation-regulated chemokine/CCL17 (TARC) is highly and specifically elevated in this disease and has been proposed as possible biomarker in HL patients. In this study, we show that pretreatment TARC levels were associated with established clinical risk factors and predictive for response to treatment in a large cohort of HL patients treated in clinical trials by the German Hodgkin Study Group...
February 2013: American Journal of Hematology
Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P Nourse, Louise A Seymour, David Gottlieb, David Ritchie, Devinder Gill, Maher K Gandhi
PURPOSE: Candidate circulating disease response biomarkers for classical Hodgkin lymphoma (cHL) might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. HRS cells are sparse within the diseased node, whereas benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. CD163(+) cells within the malignant node may be prognostic, but there is no data on serum CD163 (sCD163). The HRS-specific serum protein sTARC shows promise as a disease response biomarker...
February 1, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
T Miyagaki, M Sugaya, H Suga, S Morimura, M Kamata, H Ohmatsu, H Fujita, Y Asano, Y Tada, T Kadono, S Sato
BACKGROUND: CD26 is a multifunctional type II transmembrane glycoprotein, which also exists as a secreted isoform, soluble CD26 (sCD26). The CD26 expression on circulating T cells is decreased in some skin diseases such as cutaneous T-cell lymphoma (CTCL) and psoriasis. It remains to be determined whether sCD26 can be used as a marker of skin diseases or not. OBJECTIVE: To investigate utility of sCD26 as a diagnostic marker of skin diseases in combination with thymus and activation-regulated chemokine (TARC)...
January 2013: Journal of the European Academy of Dermatology and Venereology: JEADV
M Hnátková, H Mociková, M Trnený, J Zivný
Hodgkin's lymphoma is a lymphoproliferative disease, which differs in its morphology and therapeutic response from other lymphomas. Neoplastic cells represent only a minor cell population of the tumour, while the major part of the tumour is formed by inflammatory cells. It results from the production of cytokines and chemokines both by neoplastic cells and by inflammatory cells. An important prognostic marker in Hodgkin's lymphoma appears to be the chemokine (C-C motif) ligand 17 (CCL17), also known as thymus and activation-related chemokine (TARC)...
2009: Prague Medical Report
Antonio Di Stasi, Biagio De Angelis, Cliona M Rooney, Lan Zhang, Aruna Mahendravada, Aaron E Foster, Helen E Heslop, Malcolm K Brenner, Gianpietro Dotti, Barbara Savoldo
For the adoptive transfer of tumor-directed T lymphocytes to prove effective, there will probably need to be a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express. The Reed-Stemberg cells of Hodgkin lymphoma (HL) predominantly produce thymus- and activation-regulated chemokine/CC chemokine ligand 17 (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), which preferentially attract type 2 T helper (Th2) cells and regulatory T cells (Tregs) that express the TARC/MDC-specific chemokine receptor CCR4, thus generating an immunosuppressed tumor environment...
June 18, 2009: Blood
Christoph Hoeller, Stephen K Richardson, Lai Guan Ng, Teresa Valero, Maria Wysocka, Alain H Rook, Wolfgang Weninger
Cutaneous T-cell lymphoma (CTCL) is characterized by the accumulation of malignant CD4(+) T cells in the skin. Although the expression of adhesion molecules and chemokine receptors on CTCL cells has been studied extensively on ex vivo isolated cells, very little is known about the dynamics and mechanisms of CTCL trafficking in vivo. However, detailed knowledge of the molecular cues mediating CTCL migration may be used to interfere with their homing to the skin. We made use of real-time intravital epifluorescence video and two-photon microscopy to visualize malignant T cells from Sezary syndrome (SS), a leukemic variant of CTCL, in dermal microvessels in mouse ear skin...
April 1, 2009: Cancer Research
Daniela Buglio, Georgios V Georgakis, Shino Hanabuchi, Kazuhiko Arima, Noor M Khaskhely, Yong-Jun Liu, Anas Younes
Epigenetic changes have been implicated in silencing several B-cell genes in Hodgkin and Reed-Sternberg cells (HRS) of Hodgkin lymphoma (HL), and this mechanism has been proposed to promote HRS survival and escape from immunosurveillance. However, the molecular and functional consequences of histone deacetylase (HDAC) inhibition in HL have not been previously described. In this study, we report that the HDAC inhibitor vorinostat induced p21 expression and decreased Bcl-xL levels causing cell-cycle arrest and apoptosis...
August 15, 2008: Blood
Caroline Thielen, Vincent Radermacher, Mounir Trimeche, Florence Roufosse, Michel Goldman, Jacques Boniver, Laurence de Leval
The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma cells and/or intra-tumoral surrounding cells. Paraffin-embedded specimens from 50 patients diagnosed with peripheral T-cell lymphomas, either unspecified (PTCL-U, n=30) or angioimmunoblastic (AITL, n=20) were morphologically assessed for intra-tumoral eosinophilia and analyzed by immunohistochemistry using specific antibodies directed against TARC, IL-5, RANTES, and eotaxin...
September 2008: Leukemia Research
Marijke Niens, Lydia Visser, Ilja M Nolte, Gerrit van der Steege, Arjan Diepstra, Pablo Cordano, Ruth F Jarrett, Gerard J Te Meerman, Sibrand Poppema, Anke van den Berg
Hodgkin lymphoma (HL) is characterized by a minority of neoplastic Hodgkin-Reed Sternberg (HRS) cells surrounded by a non-neoplastic reactive infiltrate. As immunological mechanisms appear to be crucial in classical HL pathogenesis, altered serum chemokine levels might be related to disease activity. Serum levels of nine chemokines were examined in 163 untreated HL patients and 334 controls. We investigated single nucleotide polymorphisms (SNPs) for association with serum CCL17 (thymus and activation-regulated chemokine, TARC) levels and HL susceptibility...
March 2008: British Journal of Haematology
Yue Ma, Lydia Visser, Han Roelofsen, Marcel de Vries, Arjan Diepstra, Gustaaf van Imhoff, Tineke van der Wal, Marjan Luinge, Gloria Alvarez-Llamas, Hans Vos, Sibrand Poppema, Roel Vonk, Anke van den Berg
Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin lymphoma (HL) secrete factors that interact with inflammatory background cells and may serve as biomarkers for disease activity. To detect new proteins related to pathogenesis, we analyzed the secretome of HRS cells. Proteins in cell culture supernatant of 4 HL cell lines were identified using 1DGE followed by in-gel trypsin digestion and LC-MS/MS. In total, 1290 proteins, including 368 secreted proteins, were identified. Functional grouping of secreted proteins revealed 37 proteins involved in immune response...
February 15, 2008: Blood
Maria Teresa Fierro, Alessandra Comessatti, Pietro Quaglino, Michela Ortoncelli, Simona Osella Abate, Renata Ponti, Mauro Novelli, Maria Grazia Bernengo
BACKGROUND: Erythroderma can be caused by inflammatory dermatoses or cutaneous T-cell lymphoma. Even if chemokines and their receptors are involved in the skin-selective lymphocyte recruitment, their role in inflammatory erythroderma is yet unclear. OBJECTIVE: To evaluate the chemokine release (TARC, MDC, IP-10) and to define the expression pattern of Th1- (CCR5, CXCR3) and Th2-related (CCR4) chemokine receptors in inflammatory erythroderma and Sézary syndrome (SS)...
2006: Dermatology: International Journal for Clinical and Investigative Dermatology
Takashi Ishida, Ryuzo Ueda
Leukocyte trafficking, which is critically regulated by chemokines and their receptors, shares many of the characteristics of tumor cell infiltration and metastasis. Expression of CC chemokine receptor 4 (CCR4) by tumor cells is associated with skin involvement, but CCR4 also has an important role in normal and tumor immunity. In a subset of patients with CCR4(+) T-cell leukemia/lymphoma, the tumor cells themselves function as regulatory T (Treg) cells, contributing to tumor survival in the face of host antitumor immune responses...
November 2006: Cancer Science
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"